Download PDFPDF

330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address